Free lookups: 0/3 Unlock Pro
Clinical reference Find a medicine
Ctrl K
0 of 3 free lookups remaining Upgrade
New search Medicine profile Metronidazole / Diloxanide / Simethicone

Clinical medicine profile

Metronidazole / Diloxanide / Simethicone

Nitroimidazole antimicrobial / antiprotozoal

POM
Evidence state Source-linked Review date not recorded
Route
ORAL / IV / TOPICAL / VAGINAL
Schedule
POM
ATC
Not assigned
PPB status
registered
Patient advice Check interactions
01 Risk first

Safety essentials

The information most likely to change a prescribing or dispensing decision.

Contraindications

  • Hypersensitivity to nitroimidazoles.
  • First trimester use traditionally avoided unless essential (practice evolving — follow current obstetric guidance).
  • Disulfiram within 2 weeks.

Precautions

  • Avoid alcohol during and for 24–72 h after (disulfiram-like reaction).
  • Neurologic toxicity with prolonged/high dose (neuropathy, seizures).
  • Metallic taste common.
  • Dark urine possible.
02 Point of care

Dosing matrix

Population and organ-function guidance, shown together for faster comparison.

Adult

Dosing is indication-, age-, weight- and organ-function-specific for this INN. Do not use class averages for high-risk patients. Confirm the exact regimen in the current SmPC and Kenya Standard Treatment Guidelines. Typical professional workflow: (1) confirm indication, (2) check renal/hepatic function, (3) screen interactions/allergies, (4) select dose/route/duration, (5) define monitoring.

Paediatric

Paediatric dosing is weight- and age-based; use a paediatric formulary / SmPC. Do not extrapolate adult tablets without calculation.

Renal

Metabolites accumulate in renal failure; review dosing in ESRD.

  • CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Hepatic

Hepatic metabolism — reduce dose in severe liver disease.

03 Clinical use

Use, effects & interactions

Indications

  • see under metronidazole, diloxanide and simethicone respectively.
  • Clinical selection for Metronidazole / Diloxanide / Simethicone should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
  • Class context: Nitroimidazole antimicrobial / antiprotozoal.
  • Confirm site-specific dose, duration and monitoring before prescribing.

Adverse effects

  • [Metronidazole] GI discomfort, anorexia, metallic taste, dry mouth, headache, skin rash, vertigo, depression, insomnia, drowsiness, urethral dis- comfort, darkened urine, transient fall in BP, temporary leucopenia, bone marrow depression, transient epileptic seizure, furred tongue. [Simethicone] Adverse reactions vary by agent.
  • Counsel on common predictable effects and serious warning symptoms (allergy, severe rash, jaundice, unusual bleeding, severe GI symptoms, neurological changes).
  • Report suspected ADRs via national pharmacovigilance channels.
  • Cornerstone for anaerobic coverage and protozoa (giardia, amoeba, trichomonas).
  • Combine with other agents for mixed aerobic–anaerobic infections as indicated.
  • Warn every patient about alcohol.
04 Pharmacology

Mechanism & disposition

see under metronidazole, diloxanide and simethicone respectively.

see under metronidazole, diloxanide and si…Nitroimidazoles are reduced by ferredoxin-…Selective for anaerobic/microaerophilic or…
Read complete mechanism

see under metronidazole, diloxanide and simethicone respectively. Nitroimidazoles are reduced by ferredoxin-like systems in anaerobic bacteria and protozoa to reactive nitro radicals that damage DNA and other macromolecules, causing cell death. Selective for anaerobic/microaerophilic organisms.

Onset

1–2 hours

Duration

8–24 hours

Route

ORAL / IV / TOPICAL / VAGINAL

Distribution

including abscesses and CSF. Hepatic

05 Special populations

Pregnancy, lactation & diet

Pregnancy

[Metronidazole] [Metronidazole] Widely used in later pregnancy for BV/trichomoniasis in many protocols; avoid unnecessary first-trimester exposure — follow current guidance. [Simethicone] Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist.

Lactation

[Metronidazole] [Metronidazole] Single-dose regimens often compatible with pumping/timing advice; prolonged high dose — review. [Simethicone] Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data.

06 Kenya market

Brands & loaded prices

From
Median
Listings0
BrandManufacturerPackObserved price
No reviewed brand listings are linked yet.
07 Provenance

Sources & review state

Primary sourceLocal active-ingredient clinical extract; RxNorm (NLM RxNav); PubChem; Component monographs (multi-source pipeline)
Last reviewedNot recorded
EvidenceSource-linked
Open source document ↗

Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.